Integra LifeSciences Aims To Shutter Two Plants, Discontinue Low-Growth Products
This article was originally published in The Gray Sheet
Executive Summary
The plans are part of a strategy to consolidate manufacturing operations while prioritizing fast-growing, high-margin regenerative medicine products.